Oral GUCY2C Ligand Blocks Colorectal Tumor Progression in Patients
Abstract
Colorectal cancer is the 4th most common cancer in the United States. To date, no tenable chemoprevention agents have been identified for widespread use to minimize the burden of this common cancer. Previously the study team has produced preclinical as well as early clinical data in support of a novel agent class, GUCY2C agonists, as a potential chemopreventive agent. The current trial will randomize two types of patients: those with previous colorectal adenomas, as well as those with documented colorectal cancer awaiting resection. Participants of either type will receive either placebo or linaclotide 0.870mg (an FDA approved GUCY2C agonist) for 7 days. At the conclusion of drug/placebo exposure adenoma participants will undergo colonoscopy and colorectal cancer participants will undergo surgery with standardized collection of normal and abnormal tissue. Assays for a series of biomarker assays relevant to GUCY2C signaling will be collected. We hypothesize that recipients of active agent will have differential modulation of pathways relevant to colorectal carcinogenesis. Assuming benefit as well as tolerability is demonstrated, results from this study should set the stage for larger scale, longer term chemoprevention for colorectal cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2021
- Accession Number
- AD1156578
Entities
People
- David Weinberg
Organizations
- Fox Chase Cancer Center